BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 16943401)

  • 1. Celecoxib for the prevention of colorectal adenomatous polyps.
    Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
    N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib for the prevention of sporadic colorectal adenomas.
    Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
    N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.
    Solomon SD; McMurray JJ; Pfeffer MA; Wittes J; Fowler R; Finn P; Anderson WF; Zauber A; Hawk E; Bertagnolli M;
    N Engl J Med; 2005 Mar; 352(11):1071-80. PubMed ID: 15713944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
    Solomon SD; Pfeffer MA; McMurray JJ; Fowler R; Finn P; Levin B; Eagle C; Hawk E; Lechuga M; Zauber AG; Bertagnolli MM; Arber N; Wittes J;
    Circulation; 2006 Sep; 114(10):1028-35. PubMed ID: 16943394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
    N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risks and benefits of celecoxib to prevent recurrent adenomas.
    Psaty BM; Potter JD
    N Engl J Med; 2006 Aug; 355(9):950-2. PubMed ID: 16943408
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized trial of aspirin to prevent colorectal adenomas.
    Baron JA; Cole BF; Sandler RS; Haile RW; Ahnen D; Bresalier R; McKeown-Eyssen G; Summers RW; Rothstein R; Burke CA; Snover DC; Church TR; Allen JI; Beach M; Beck GJ; Bond JH; Byers T; Greenberg ER; Mandel JS; Marcon N; Mott LA; Pearson L; Saibil F; van Stolk RU
    N Engl J Med; 2003 Mar; 348(10):891-9. PubMed ID: 12621133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.
    Baron JA; Sandler RS; Bresalier RS; Quan H; Riddell R; Lanas A; Bolognese JA; Oxenius B; Horgan K; Loftus S; Morton DG;
    Gastroenterology; 2006 Dec; 131(6):1674-82. PubMed ID: 17087947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.
    Sandler RS; Halabi S; Baron JA; Budinger S; Paskett E; Keresztes R; Petrelli N; Pipas JM; Karp DD; Loprinzi CL; Steinbach G; Schilsky R
    N Engl J Med; 2003 Mar; 348(10):883-90. PubMed ID: 12621132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
    Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
    Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group.
    Baron JA; Beach M; Mandel JS; van Stolk RU; Haile RW; Sandler RS; Rothstein R; Summers RW; Snover DC; Beck GJ; Bond JH; Greenberg ER
    N Engl J Med; 1999 Jan; 340(2):101-7. PubMed ID: 9887161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis.
    Steinbach G; Lynch PM; Phillips RK; Wallace MH; Hawk E; Gordon GB; Wakabayashi N; Saunders B; Shen Y; Fujimura T; Su LK; Levin B; Godio L; Patterson S; Rodriguez-Bigas MA; Jester SL; King KL; Schumacher M; Abbruzzese J; DuBois RN; Hittelman WN; Zimmerman S; Sherman JW; Kelloff G
    N Engl J Med; 2000 Jun; 342(26):1946-52. PubMed ID: 10874062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress.
    Hawk E; Viner JL
    Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):185-7. PubMed ID: 17301246
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
    Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
    Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
    Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group.
    Schatzkin A; Lanza E; Corle D; Lance P; Iber F; Caan B; Shike M; Weissfeld J; Burt R; Cooper MR; Kikendall JW; Cahill J
    N Engl J Med; 2000 Apr; 342(16):1149-55. PubMed ID: 10770979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
    Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
    Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.